Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SPC1001 Low in Essential Hypertension
NCT07064525Phase 2Enrolling by invitation
- Sponsor
- Shinpoong Pharma
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of candesartan + amlodipine + indapamide in essential hypertension, sponsored by Shinpoong Pharma. Started Dec 2024; status: enrolling by invitation.
02
Drugs
candesartan + amlodipine + indapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07064525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064525.